Ardelyx Appoints Experienced Finance Executive, Sue Hohenleitner, as Chief Financial Officer
Rhea-AI Summary
Ardelyx (Nasdaq: ARDX) announced the appointment of Sue Hohenleitner as Chief Financial Officer, effective November 4, 2025. Hohenleitner brings more than 30 years of corporate finance and operations experience and served most recently as VP and CFO of Johnson & Johnson Innovative Medicine North America, where she led financial strategies for a $36 billion commercial business. She is a CPA and CMA with a BS in Accounting and an MBA. Hohenleitner will assume the role following Ardelyx’s third quarter 2025 financial reporting; current CFO and COO Justin Renz will continue in his role through the filing of Ardelyx’s Form 10-Q.
This leadership change is positioned to support Ardelyx’s commercial expansion and long-term growth strategy while the company executes near-term financial reporting and transition steps.
Positive
- Appointment effective November 4, 2025
- Executive brings 30+ years of finance and operations experience
- Previously led financial strategy for a $36 billion commercial business
Negative
- Transition window limited until completion of Q3 2025 reporting and Form 10-Q filing
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced the appointment of Sue Hohenleitner as Chief Financial Officer (CFO), effective November 4, 2025. Ms. Hohenleitner is a proven financial leader, bringing more than 30 years of experience in corporate finance, strategic planning, investor relations and operations across a variety of therapeutic areas and stages of development. She has a demonstrated track record of driving organizational transformation, building financial strength and driving sustainable growth across commercial and development-stage products. Ms. Hohenleitner most recently served as the Vice President and Chief Financial Officer of Johnson & Johnson (J&J) Innovative Medicine North America (NA), leading financial strategies for a
“I am thrilled to welcome Sue to the Ardelyx leadership team,” said Mike Raab, president and chief executive officer of Ardelyx. “Sue is an accomplished and visionary financial leader whose proven ability to execute growth strategies and drive operational excellence makes her an exceptional addition to our company. Her forward-thinking approach, strategic insight and deep understanding of our industry will be instrumental as we expand our commercial success and pursue new opportunities for growth. Sue’s leadership and financial discipline will help accelerate Ardelyx’s momentum, strengthen our foundation and position the company for long-term success, helping us to deliver meaningful value for patients, employees and shareholders alike.”
“I am very excited to join Ardelyx at this important time in its evolution,” said Ms. Hohenleitner. “With two first-in-class medicines helping patients and plans for expansion in the years ahead, I look forward to working with the team to shape strategic paths for long-term growth and innovation for patients everywhere, to develop the next generation of important medicines and to help patients who need our drugs the most.”
Prior to joining Ardelyx, Ms. Hohenleitner enjoyed a 28-year career at J&J where she led multiple finance organizations in areas such as supply chain, innovation, commercial, business development, investor relations, acquisitions and divestitures, and finance planning and analysis. As VP and CFO of J&J Innovative Medicine NA, Ms. Hohenleitner led a number of strategic initiatives that resulted in greater efficiencies, effectiveness and funding for growth. Ms. Hohenleitner was also a critical partner during the acquisition of two significant deals which resulted in successful commercial launches.
Ms. Hohenleitner is a Certified Public Accountant in the Commonwealth of Pennsylvania and a Certified Management Accountant. She earned a Bachelor of Science in Accounting from La Salle University and a Master of Business Administration from Villanova University. Ms. Hohenleitner was named a Top 25 CFO in Biotech by Business & Investing.
Ms. Hohenleitner will assume the CFO role on November 4, 2025 following the completion of Ardelyx’s third quarter 2025 financial reporting. Justin Renz, the current Chief Financial and Operations Officer, will continue in his role through the filing of Ardelyx’s Quarterly Report on Form 10-Q.
About Ardelyx
Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been approved in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. For more information, please visit https://ardelyx.com/ and connect with us on X (formerly known as Twitter), LinkedIn and Facebook.
Investor and Media Contact
Caitlin Lowie
clowie@ardelyx.com
FAQ
When will Sue Hohenleitner start as CFO of Ardelyx (ARDX)?
What experience does Ardelyx CFO Sue Hohenleitner bring to ARDX?
Why is the Ardelyx CFO change happening around Q3 2025 reporting?
Who will cover CFO responsibilities at Ardelyx until the transition is complete?
Does Sue Hohenleitner hold professional finance credentials relevant to ARDX investors?
How might the ARDX CFO appointment affect Ardelyx’s commercial strategy?
